Uncertain translation, uncertain benefit and uncertain risk: Ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Bioethics 27 (2):89-96 (2013)
The discovery of induced pluripotent stem (iPS) cells in 2006 was heralded as a major breakthrough in stem cell research. Since then, progress in iPS cell technology has paved the way towards clinical application, particularly cell replacement therapy, which has refueled debate on the ethics of stem cell research. However, much of the discourse has focused on questions of moral status and potentiality, overlooking the ethical issues which are introduced by the clinical testing of iPS cell replacement therapy. First-in-human trials, in particular, raise a number of ethical concerns including informed consent, subject recruitment and harm minimisation as well as the inherent uncertainty and risks which are involved in testing medical procedures on humans for the first time. These issues, while a feature of any human research, become more complex in the case of iPS cell therapy, given the seriousness of the potential risks, the unreliability of available animal models, the vulnerability of the target patient group, and the high stakes of such an intensely public area of science. Our paper will present a detailed case study of iPS cell replacement therapy for Parkinson's disease to highlight these broader ethical and epistemological concerns. If we accept that iPS cell technology is fraught with challenges which go far beyond merely refuting the potentiality of the stem cell line, we conclude that iPS cell research should not replace, but proceed alongside embryonic and adult somatic stem cell research to promote cross-fertilisation of knowledge and better clinical outcomes
|Keywords||stem cells Parkinson's disease research ethics first‐in‐human trials risk|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
Sophie L. Niemansburg, Michelle G. J. L. Habets, Wouter J. A. Dhert, Johannes J. M. van Delden & Annelien L. Bredenoord (2015). Participant Selection for Preventive Regenerative Medicine Trials: Ethical Challenges of Selecting Individuals at Risk: Figure 1. Journal of Medical Ethics 41 (11):914-916.
Similar books and articles
Mark T. Brown (2009). Moral Complicity in Induced Pluripotent Stem Cell Research. Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
Mark Brown (2013). No Ethical Bypass of Moral Status in Stem Cell Research. Bioethics 27 (1):12-19.
David Magnus (2010). Translating Stem Cell Research: Challenges at the Research Frontier. Journal of Law, Medicine & Ethics 38 (2):267-276.
Nikolaus Knoepffler (2004). Stem Cell Research: An Ethical Evaluation of Policy Options. Kennedy Institute of Ethics Journal 14 (1):55-74.
Zubin Master & G. K. D. Crozier (2012). The Ethics of Moral Compromise for Stem Cell Research Policy. Health Care Analysis 20 (1):50-65.
Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter (2003). Safety Issues In Cell-Based Intervention Trials. Fertility and Sterility 80 (5):1077-1085.
Glenn McGee & Arthur L. Caplan (1999). The Ethics and Politics of Small Sacrifices in Stem Cell Research. Kennedy Institute of Ethics Journal 9 (2):151-158.
Bernard Dickens, International Society for Stem Cell Research (ISSCR) Guidelines for the Conduct of Human Embryonic Stem Cell Research (December 2006).
Hossam E. Fadel (2012). Developments in Stem Cell Research and Therapeutic Cloning: Islamic Ethical Positions, a Review. Bioethics 26 (3):128-135.
Insoo Hyun (2010). Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges. Journal of Law, Medicine & Ethics 38 (2):277-285.
Rebecca Dresser (2010). Stem Cell Research as Innovation: Expanding the Ethical and Policy Conversation. Journal of Law, Medicine & Ethics 38 (2):332-341.
Philip J. Nickel (2008). Ethical Issues in Human Embryonic Stem Cell Research. In Kristen Renwick Monroe, Ronald B. Miller & Jerome Tobis (eds.), Fundamentals of the Stem Cell Debate: The Scientific, Religious, Ethical & Political Issues. University of California Press
Demetrio Neri (2011). The Race Toward 'Ethically Universally Acceptable' Human Pluripotent (Embryonic-Like) Stem Cells: Only a Problem of Sources? Bioethics 25 (5):260-266.
Tamra Lysaght & Alastair V. Campbell (2013). Broadening the Scope of Debates Around Stem Cell Research. Bioethics 27 (5):251-256.
Bernard Lo & Lindsay Parham (2010). Resolving Ethical Issues in Stem Cell Clinical Trials: The Example of Parkinson Disease. Journal of Law, Medicine & Ethics 38 (2):257-266.
Added to index2011-07-05
Total downloads16 ( #189,690 of 1,778,413 )
Recent downloads (6 months)1 ( #291,352 of 1,778,413 )
How can I increase my downloads?